The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis

Abstract

Aim Conduct a systematic review with meta-analysis to determine the association between incident chemotherapy-induced neutropenia (CIN) and either diabetes mellitus (DM) or hyperglycemia in patients with cancer. Methods Observational studies in cancer patients of any age receiving chemotherapy and having diabetes or hyperglycemia either during or before chemotherapy induction were included. Studies were retrieved by searching four databases (PubMed, EBSCO, ProQuest, and Cochrane) and cross-referencing. The metric for combining studies was the odds ratio (OR). Results were pooled using a random-effects model, while heterogeneity and inconsistency were assessed using the Q and I2 statistic, respectively. Potential small-study effects were assessed using the funnel plot. Results Ten studies met the criteria for inclusion. Overall, the odds of having CIN were 32% higher among cancer patients with either DM or hyperglycemia compared with those without DM or hyperglycemia (OR = 1.32, 95% CI, 1.06–1.64). Statistically significant heterogeneity and inconsistency were found (Q = 33.15, p < 0.05, I2 = 72.9%). Funnel plot asymmetry reflecting potential small-study effects was observed. Conclusions Diabetes mellitus and hyperglycemia may be associated with an increased risk for CIN among cancer patients. However, additional well-designed studies are needed before any final and definitive recommendations can be made.

Impact of Diabetes Complications on Breast Cancer Screening, Diagnosis, and Prognosis among Elderly Women with Pre-existing Diabetes Using the SEER-Medicare Dataset

“…Unlike previous research that suggested that receipt of chemotherapy may be associated with an increased risk of death (Alenzi & Kelley, 2017;Brunello, Kapoor, & Extermann, 2011;Crawford et al, 2008;Lega et al, 2013;Matias Cdo et al, 2013;Peairs et al, 2011), our findings revealed that chemotherapy was not associated with all-cause mortality after controlling for diabetes severity, cancer severity and all other possible covariates. This may indicate that the association between chemotherapy-related toxicity and mortality is mediated by diabetes severity since all the previous studies did not control for diabetes severity.…”

Impact of Steroid-Induced Diabetes on Prognosis of Patients with Aggressive Lymphoid Malignancies: A Prospective Study

“…Therefore, it is proposed that hyperglycemia may increase the risk of chemotherapy-induced neutropenia 14 . However, since hyperglycemia and diabetes are previously unrecognized as risk factors for chemotherapyinduced neutropenia, the collective evidence of their effect on developing chemotherapy-induced neutropenia during chemotherapy among patients with cancer needs further confirmation 15,16 .…”

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

“…CIN is specifically associated with older age, poorer functional and nutritional status, the presence of significant comorbidities, certain types of cancer, previous chemotherapy cycles, disseminated diseases, particular chemotherapy regimens, and combined therapy. Cancer patients with diabetes mellitus or hyperglycemia have a 32% higher chance of developing CIN than patients without these two conditions 12 .…”